BDRX VS TIVC Stock Comparison

Performance

BDRX
10/100

BDRX returned -98.01% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

TIVC
10/100

TIVC returned -99.15% in the last 12 months. Based on SPY's performance of -21.10%, its performance is below average giving it a score of 10 of 100.

Volatility

BDRX
71/100

BDRX has had a higher than average amount of volatility over the last 12 months giving it a score of 71 of 100.

TIVC
35/100

TIVC has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.

Sentiment

BDRX

"Sentiment" not found for BDRX

TIVC
71/100

TIVC had a bullish sentiment score of 70.99% across Twitter and StockTwits over the last 12 months. It had an average of 42.03 posts, 13.23 comments, and 71.62 likes per day.

Technicals

BDRX

"Technicals" not found for BDRX

TIVC
10/100

TIVC receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

BDRX

"Earnings" not found for BDRX

TIVC
100/100

TIVC has missed earnings 1 times in the last 20 quarters.

Profit

BDRX

"Profit" not found for BDRX

TIVC
10/100

Out of the last 11 quarters, TIVC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

Biodexa Pharmaceuticals plc American Depositary Shs Summary

Nasdaq / BDRX

Healthcare

Biotechnology

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Tivic Health Systems, Inc. Common Stock Summary

Nasdaq / TIVC

Healthcare

Medical - Devices

Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

Power up your portfolio